Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

Company Overview - Drugs Made In America Acquisition II Corp. is a blank check company incorporated in the Cayman Islands, aimed at effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses [5] - The company has not selected any specific business combination target and has not engaged in substantive discussions with any potential targets [5] - The company intends to focus its search for businesses in the pharmaceutical industry, aiming to mitigate risks in the U.S. medical supply chain by investing in companies that reduce reliance on concentrated geographic production of pharmaceuticals [5] Initial Public Offering (IPO) Details - The company announced the pricing of its initial public offering of 50,000,000 units at $10.00 per unit, with units expected to trade on Nasdaq under the ticker symbol "DMIIU" starting September 25, 2025 [1] - Each unit consists of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination [1] - The offering is expected to close on September 26, 2025, subject to customary closing conditions [1] - Underwriters have a 45-day option to purchase up to an additional 7,500,000 units to cover over-allotments [1] Legal and Regulatory Information - A registration statement on Form S-1 relating to these securities has been filed with the SEC and was declared effective on September 24, 2025 [3] - The offering is being made only by means of a prospectus, which can be obtained from Cantor Fitzgerald & Co. or the SEC website [3]